Lonoctocog alfa

DB13998ApprovedInvestigationalHemostatics

Lonoctocog alfa is a recombinant Factor VIII used to treat hemophilia A to control bleeding.

Mechanism: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).
Curator reviewed
Primary indication: For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.Curator reviewed · 2 structured indications
First approval: Canada, 2016 · United States, 2016 · European Union, 2021
Also known as: rVIII-SingleChain
Code names: CSL627
Brand names: Afstyla

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of September 15, 2026

12Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

43Marketed productsAcross 7 countries and 4 labellers

38+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lonoctocog alfa, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.